Whole parasite malaria vaccine to be manufactured for clinical trials
Sanaria Inc. and the PATH Malaria Vaccine Initiative has officially opened a one-of-a-kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.
The event marks a major milestone in the effort to translate Sanaria’s approach into an effective weapon against the deadly malaria parasite Plasmodium (P.) falciparum.
